



For Immediate Release

Contact: Bob Linton  
Dudnyk Public Relations  
+1.267.532.1298  
[blinton@dudnyk.com](mailto:blinton@dudnyk.com)

Fujirebio Diagnostics, Inc. Names Monte W. Wiltse,  
Vice President of Sales and Marketing

**MALVERN, Pa. – July 25, 2005** – Fujirebio Diagnostics, Inc. (FDI), a world leader in *in-vitro* diagnostics, today announced that Monte W. Wiltse has joined the company as its new vice president of sales and marketing. Wiltse will have primary responsibility for leading FDI's marketing and sales efforts, and directing the company's product management and marketing communication activities.

Wiltse brings 14 years of experience in the diagnostics industry to his new position. Prior to joining FDI, Wiltse held several senior-level marketing management positions with Bayer Healthcare Diagnostics where he was responsible for molecular testing systems and the oncology immunoassay reagent product line. Prior to Bayer Healthcare, he worked for UroCor, Inc. (formerly CytoDiagnostics) where he held a number of sales and marketing positions.

"FDI is at a crucial stage in its development as we look to launch new biomarkers with the potential to detect and monitor specific cancers in their early stages," commented FDI president and COO Paul Touhey. "Monte will play a critical role in helping us develop and deepen distributor relationships to launch these new products, as well as effectively execute the company's marketing plan. A capable and experienced executive, we are pleased to have Monte become part of our senior management team."

-more-

Wiltse earned his MBA from the University of Oklahoma and his BA from Washburn University. He currently resides in Danbury, CT. and will be relocating to the Philadelphia area with his wife, Maureen, and their 3 children.

**About FDI**

Fujirebio Diagnostics, Inc. (FDI) is a premier diagnostics company and the industry leader in tumor marker assays. FDI specializes in the clinical development, manufacturing and commercialization of in vitro diagnostic products for the management of human disease states, with an emphasis in oncology. In November 1998, Fujirebio, Inc. of Tokyo, Japan, acquired the company, formerly known as Centocor Diagnostics. FDI utilizes its worldwide distribution network to enable access by physicians and patients to its diagnostic products. For more information about FDI, please call 610-240-3800 or visit [www.fdi.com](http://www.fdi.com).

# # #